Literature DB >> 19806344

Nicotine withdrawal and kappa-opioid receptors.

Michael J McCarthy1, Hailing Zhang, Norton H Neff, Maria Hadjiconstantinou.   

Abstract

RATIONALE: The synthesis and release of dynorphin are increased in the caudate/putamen (CPU) and nucleus accumbens (NAc) of nicotine-withdrawn mice, suggesting a role in the nicotine abstinence syndrome.
OBJECTIVES: This study aims to investigate the consequences of enhanced dynorphinergic activity on kappa-opioid receptor (KOPr) expression, coupling, and function in CPU and NAc following chronic nicotine administration and withdrawal.
METHODS: Mice were injected with nicotine-free base 2 mg/kg, or saline, sc, four times daily for 14 days and experiments performed at 24, 48, and 72 h after drug discontinuation. KOPr binding and mRNA were evaluated by [(3)H]-U69,593 autoradiography and in situ hybridization. KOPr coupling and function were investigated by agonist (U69-593)-stimulated [(35)S]GTPgammaS binding autoradiography and inhibition of adenylyl cyclase activity.
RESULTS: KOPr binding density and mRNA in CPU and NAc were unaltered during nicotine withdrawal; however, KPOr mRNA was increased in midbrain. U69,593-stimulated [(35)S]GTPgammaS binding was attenuated in both striatal regions, especially in NAc. In NAc shell and core, stimulated [(35)S]GTPgammaS binding was significantly decreased by 24 h and further declined over the 72 h observation period. In CPU, significant changes were observed only at 72 h. Basal adenylyl cyclase activity decreased early during nicotine withdrawal and recovered by 48 h. Stimulation with U69,593 failed to inhibit adenylyl cyclase activity at all times studied.
CONCLUSIONS: These observations suggest that KOPr coupling and function are impaired in NAc and CPU during nicotine withdrawal, and imply receptor desensitization. KOPr desensitization might be a mechanism to ameliorate aversive behavioral symptoms, as nicotine withdrawal evolves.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19806344     DOI: 10.1007/s00213-009-1674-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  64 in total

1.  Effects of repeated withdrawal episodes, nicotine dose, and duration of nicotine exposure on the severity and duration of nicotine withdrawal in rats.

Authors:  Karen L Skjei; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2003-04-24       Impact factor: 4.530

2.  Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal.

Authors:  F Simonin; O Valverde; C Smadja; S Slowe; I Kitchen; A Dierich; M Le Meur; B P Roques; R Maldonado; B L Kieffer
Journal:  EMBO J       Date:  1998-02-16       Impact factor: 11.598

3.  Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects.

Authors:  S S Watkins; L Stinus; G F Koob; A Markou
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

4.  Dramatic decreases in brain reward function during nicotine withdrawal.

Authors:  M P Epping-Jordan; S S Watkins; G F Koob; A Markou
Journal:  Nature       Date:  1998-05-07       Impact factor: 49.962

5.  Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles.

Authors:  A L Svingos; C Chavkin; E E Colago; V M Pickel
Journal:  Synapse       Date:  2001-12-01       Impact factor: 2.562

6.  Mood and physiological effects of subcutaneous nicotine in smokers and never-smokers.

Authors:  J Foulds; J A Stapleton; N Bell; J Swettenham; M J Jarvis; M A Russell
Journal:  Drug Alcohol Depend       Date:  1997-03-14       Impact factor: 4.492

7.  Cellular sites for dynorphin activation of kappa-opioid receptors in the rat nucleus accumbens shell.

Authors:  A L Svingos; E E Colago; V M Pickel
Journal:  J Neurosci       Date:  1999-03-01       Impact factor: 6.167

8.  The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward.

Authors:  Hilarie C Tomasiewicz; Mark S Todtenkopf; Elena H Chartoff; Bruce M Cohen; William A Carlezon
Journal:  Biol Psychiatry       Date:  2008-07-17       Impact factor: 13.382

9.  Rodent model of nicotine abstinence syndrome.

Authors:  D H Malin; J R Lake; P Newlin-Maultsby; L K Roberts; J G Lanier; V A Carter; J S Cunningham; O B Wilson
Journal:  Pharmacol Biochem Behav       Date:  1992-11       Impact factor: 3.533

10.  In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding.

Authors:  L J Sim; D E Selley; S R Childers
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

View more
  8 in total

Review 1.  The opioid receptors as targets for drug abuse medication.

Authors:  Florence Noble; Magalie Lenoir; Nicolas Marie
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

2.  CREB involvement in the regulation of striatal prodynorphin by nicotine.

Authors:  Michael J McCarthy; Anne-Marie Duchemin; Norton H Neff; Maria Hadjiconstantinou
Journal:  Psychopharmacology (Berl)       Date:  2011-11-17       Impact factor: 4.530

3.  Dysregulation of kappa-opioid receptor systems by chronic nicotine modulate the nicotine withdrawal syndrome in an age-dependent manner.

Authors:  Hugo A Tejeda; Luis A Natividad; James E Orfila; Oscar V Torres; Laura E O'Dell
Journal:  Psychopharmacology (Berl)       Date:  2012-06-04       Impact factor: 4.530

4.  Desensitization of δ-opioid receptors in nucleus accumbens during nicotine withdrawal.

Authors:  Michael J McCarthy; Hailing Zhang; Norton H Neff; Maria Hadjiconstantinou
Journal:  Psychopharmacology (Berl)       Date:  2010-10-13       Impact factor: 4.530

5.  Role of the kappa-opioid receptor system in stress-induced reinstatement of nicotine seeking in rats.

Authors:  Stephanie L Grella; Douglas Funk; Kathy Coen; Zhaoxia Li; A D Lê
Journal:  Behav Brain Res       Date:  2014-02-28       Impact factor: 3.332

Review 6.  Dynorphin--still an extraordinarily potent opioid peptide.

Authors:  Charles Chavkin
Journal:  Mol Pharmacol       Date:  2012-11-14       Impact factor: 4.436

Review 7.  Endogenous opioid system: a promising target for future smoking cessation medications.

Authors:  Haval Norman; Manoranjan S D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2017-03-11       Impact factor: 4.530

8.  In vivo detection of optically-evoked opioid peptide release.

Authors:  Ream Al-Hasani; Jenny-Marie T Wong; Robert T Kennedy; Michael R Bruchas; Omar S Mabrouk; Jordan G McCall; Gavin P Schmitz; Kirsten A Porter-Stransky; Brandon J Aragona
Journal:  Elife       Date:  2018-09-03       Impact factor: 8.140

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.